Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and Esketamine for Suicide Reduction in MDD
NCT05450432Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ketamine and esketamine in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Primary endpoints: Feasibility - Retention at 24 weeks, Feasibility - Drop-out Rates at 24 weeks and 1 more. Started Oct 2022; status: recruiting.
02
Drugs
ketamineesketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05450432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450432.